Abstract: A fully-automated computer-implemented system and method for generating a road network map from a remote sensing (RS) image in which the classification accuracy is satisfactory combines moving vehicle detection with spectral classification to overcome the limitations of each. Moving vehicle detections from an RS image are used as seeds to extract and characterize image-specific spectral roadway signatures from the same RS image. The RS image is then searched and the signatures matched against the scene to grow a road network map. The entire process can be performed using the radiance measurements of the scene without having to perform the complicated geometric and atmospheric conversions, thus improving computational efficiency, the accuracy of moving vehicle detection (location, speed, heading) and ultimately classification accuracy.

Abstract: Compositions, methods and uses are disclosed herein for treating male and female hidradenitis suppurativa with anti-androgen medications. Clinical examples of treatment of hidradenitis suppurativa with proxalutamide are provided. The methods, uses and composition described can be applied as treatment to mitigate an outbreak of hidradenitis suppurativa or as a prophylactic to prevent the occurrence of hidradenitis suppurativa.

Abstract: Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR-NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells.

Abstract: Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR-NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells.

Abstract: Apparatuses are disclosed for performing colorimetric assays with plucked human hair using a device adapted for that purpose. Also disclosed are methods for stabilizing a colorimetric chemical assay so that it can be transported and used as an at-home device for conducting a colorimetric chemical assay are described.

Abstract: Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR?NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells.

Abstract: The present invention relates to powder-layer three-dimensional printers (2) having a discrete supply hopper (340) and a recoater (20). The discrete supply hopper (340) is configured to transfer a build powder to the recoater (20) in a manner that enhances the uniformity of build powder layers that are dispensed from the recoater (20). In some embodiments, at least one of the discrete supply hopper and the powder hopper of the recoater is adapted to selectively contact the other, seal against the other, and/or have one partially inserted inside the other so as to diminish or prevent powder pluming during the transfer of build powder from the discrete supply hopper to the recoater.

Abstract: The present invention relates to apparatuses for distributing build powder in powder-layer three-dimensional printers (2) and for the collection of particulates of the build powder that have become suspended in the gaseous atmosphere in the vicinity of the build platform of the three-dimensional printer. These apparatuses include recoaters (20) that are particularly useful in providing uniform distribution of fine build powder across the width of the build platform or powder bed. The present invention also includes powder-layer three-dimensional printers (2) which comprise such apparatuses for distributing build powder and/or apparatuses for collecting such suspended particulates. The improved fine powder recoater (20) uses an ultrasonic transducer (30) to move powder through a sheet screen (28). The sheet screen (28) may be presented to the powder fed onto it in a narrow dispensing slot to limit the flow rate of powder from the dispenser and to provide control over the amount of powder dispensed.

Abstract: Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR—NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells.

Abstract: Described herein are interactive devices that mimic a portion of a human male and a female genitalia. The male device includes a unique bead drive assembly for providing an extending and retracting motion. Also included on the male device is a massager sub-assembly able to inflate and deflate while being able to slide along a shaft of the male device. The female device includes a clamshell constrictor having an inflation mechanism that is able to provide a squeezing motion as well as being able to slide back and forth within the body of the female device. Also disclosed herein are methods of communication and interaction between a pair of interactive devices or multiple interactive devices. Finally, methods of managing interactive sessions between multiple interactive devices are also described.

Abstract: Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR-NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells.

Abstract: The present invention discloses compositions, methods, and systems of treating female sexual dysfunction by stimulating the contraction of the smooth muscle of the nipple. The smooth muscle in the nipple expresses trace amine associated receptors and thus can be contracted through a class of trace amine associated receptor agonists such as octopamine or tyramine, but any agent that promotes contraction of smooth muscle can be considered for the methods and compositions described herein. The contraction of the smooth muscle erects the nipple and increases female sexual arousal. The smooth muscle stimulatory compound can be formulated in a solution, foam, ointment, gel, spray, lotion, powder, topical cream, emulsion, slow release capsule or any similar method, compound, or delivery vehicle including a pre-wetted gauze or cotton pad. Additionally, the disclosed composition can be used to improve the quality of a sexual experience, e.g.

Abstract: Systems, methods, and kits for treating, preventing, and diagnosing viral infection using an androgen mediated pathway are described. Additionally, methods and kits for guiding treatment of viral respiratory disease are described by a method for testing for polymorphisms in the androgen receptor gene. Further, systems and methods for treatment of viral respiratory disease with various anti-androgens is detailed. Finally, systems, methods, and kits for treating, preventing, and diagnosing SARS-CoV-2 (COVID-19) are presented.

Abstract: Compositions and methods are disclosed herein for treating female pattern hair loss with a topical composition used to remove minoxidil from the hairs. A method for diagnosing subjects in need of a topical composition used to remove minoxidil from the hair treatment and guiding the application of a topical composition used to remove minoxidil from the hair treatment are also described. Additionally, a method for diagnosing a subject at high risk for female pattern hair loss who will likely respond to topical composition used to remove minoxidil from the hair prophylactic treatment is described. A method for combining the composition described herein with topical minoxidil for androgenetic alopecia is described. In addition, cosmetic compositions are described as well as methods of improving the appearance of hair following application of minoxidil.

Abstract: The present disclosure includes methods, systems, kits and compositions for treating, preventing and diagnosing viral infections, specifically SARS-CoV-2 infections, with an anti-androgen and anti-thyroid medication, a thyroid receptor antagonist, a TGF-? inhibitor or a combination thereof. The present disclosure also describes methods and compositions for the treatment of viral respiratory diseases, specifically SARS-CoV-2 infections, including anti-androgens, anti-thyroid medications, thyroid receptor antagonists, TGF-? inhibitors, RXR inhibitors, furin inhibitors or other agents to disrupt the androgen signaling.

Abstract: Compositions and methods are disclosed herein for treating female pattern hair loss with phytoestrogens. A method for diagnosing subjects in need of a phytoestrogen treatment and guiding the application of a phytoestrogen treatment are also described. Additionally, a method for diagnosing a subject at high risk for female pattern hair loss who will likely respond to phytoestrogen prophylactic treatment is described. A method for combining the composition described herein with topical minoxidil for androgenetic alopecia is described.

Abstract: Systems, methods, and kits for treating, preventing, and diagnosing viral infection using an androgen mediated pathway are described. Additionally, methods and kits for guiding treatment of viral respiratory disease are described by a method for testing for polymorphisms in the androgen receptor gene. Further, systems and methods for treatment of viral respiratory disease with various anti-androgens is detailed. Finally, systems, methods, and kits for treating, preventing, and diagnosing SARS-CoV-2 (COVID-19) are presented.

Abstract: Systems, methods, and kits for treating, preventing, and diagnosing viral infection using an androgen mediated pathway are described. Additionally, methods and kits for guiding treatment of viral respiratory disease are described by a method for testing for polymorphisms in the androgen receptor gene. Further, systems and methods for treatment of viral respiratory disease with various anti-androgens is detailed. Finally, systems, methods, and kits for treating, preventing, and diagnosing SARS-CoV-2 (COVID-19) are presented.

Abstract: The present disclosure includes methods, systems, kits and compositions for treating, preventing and diagnosing viral infections, specifically SARS-CoV-2 infections, with an anti-androgen and anti-thyroid medication, a thyroid receptor antagonist, a TGF-? inhibitor or a combination thereof. The present disclosure also describes methods and compositions for the treatment of viral respiratory diseases, specifically SARS-CoV-2 infections, including anti-androgens, anti-thyroid medications, thyroid receptor antagonists, TGF-? inhibitors, RXR inhibitors, furin inhibitors or other agents to disrupt the androgen signaling.